Logo do repositório
 
Publicação

Therapeutic avenues for γδ T cells in cancer

2023Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorCosta, Gonçalo Palrão
dc.contributor.authorMensurado, Sofia
dc.contributor.authorSilva-Santos, Bruno
dc.date.accessioned2023-11-30T14:20:50Z
dc.date.available2023-11-30T14:20:50Z
dc.date.issued2023
dc.description© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.pt_PT
dc.description.abstractγδ T cells are regarded as promising effector lymphocytes for next-generation cancer immunotherapies. In spite of being relatively rare in human peripheral blood, γδ T cells are more abundant in epithelial tissues where many tumors develop, and have been shown to actively participate in anticancer immunity as cytotoxic cells or as "type 1" immune orchestrators. A major asset of γδ T cells for tackling advanced cancers is their independence from antigen presentation via the major histocompatibility complex, which clearly sets them apart from conventional αβ T cells. Here we discuss the main therapeutic strategies based on human γδ T cells. These include antibody-based bispecific engagers and adoptive cell therapies, either focused on the Vδ1+ or Vδ2+ γδ T-cell subsets, which can be expanded selectively and differentiated or engineered to maximize their antitumor functions. We review the preclinical data that supports each of the therapeutic strategies under development; and summarize the clinical trials being pursued towards establishing γδ T cell-based treatments for solid and hematological malignancies.pt_PT
dc.description.sponsorshipThis study was funded by Fundação para a Ciência e Tecnologia of the Portuguese Ministério da Ciência, Tecnologia e Ensino Superior (PTDC/MED-ONC/6829/2020 to BS-S and 2021.01953.CEECIND to SM).pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationJ Immunother Cancer. 2023 Nov 24;11(11):e007955pt_PT
dc.identifier.doi10.1136/jitc-2023-007955pt_PT
dc.identifier.eissn2051-1426
dc.identifier.urihttp://hdl.handle.net/10451/61037
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherBMJ Publishing Grouppt_PT
dc.relationDissecting regulators of anti-tumor gamma-delta T cells for improved solid cancer immunotherapy
dc.relation.publisherversionhttps://jitc.bmj.com/pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/pt_PT
dc.subjectImmunotherapy, Activept_PT
dc.subjectImmunotherapy, Adoptivept_PT
dc.subjectT-Lymphocytespt_PT
dc.titleTherapeutic avenues for γδ T cells in cancerpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleDissecting regulators of anti-tumor gamma-delta T cells for improved solid cancer immunotherapy
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/Concurso para Financiamento de Projetos de Investigação Científica e Desenvolvimento Tecnológico em Todos os Domínios Científicos - 2020/PTDC%2FMED-ONC%2F6829%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/CEEC IND4ed/2021.01953.CEECIND%2FCP1673%2FCT0007/PT
oaire.citation.issue11pt_PT
oaire.citation.titleJournal for ImmunoTherapy of Cancerpt_PT
oaire.citation.volume11pt_PT
oaire.fundingStreamConcurso para Financiamento de Projetos de Investigação Científica e Desenvolvimento Tecnológico em Todos os Domínios Científicos - 2020
oaire.fundingStreamCEEC IND4ed
person.familyNameMensurado Santos
person.familyNameSilva-Santos
person.givenNameSofia
person.givenNameBruno
person.identifierhttps://scholar.google.com/citations?user=83kKWFAAAAAJ&hl=en&oi=ao
person.identifier.ciencia-idBA10-56F0-7CAD
person.identifier.ciencia-idD51E-6517-BE6A
person.identifier.orcid0000-0002-5157-0033
person.identifier.orcid0000-0003-4141-9302
person.identifier.scopus-author-id6505885924
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationd8b0a706-823b-47f8-9b03-6ae6b5b7e494
relation.isAuthorOfPublicationf313ff02-41ee-4014-88a1-bd641b6219bf
relation.isAuthorOfPublication.latestForDiscoveryd8b0a706-823b-47f8-9b03-6ae6b5b7e494
relation.isProjectOfPublication680a2311-b983-40df-9462-ccfda4579fb7
relation.isProjectOfPublication4a0f2f5d-eaa0-43c2-9e6d-31091b08f53d
relation.isProjectOfPublication.latestForDiscovery680a2311-b983-40df-9462-ccfda4579fb7

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Therapeutic_avenues.pdf
Tamanho:
673.16 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

FM - Artigos em Revistas Internacionais
IMM - Artigos em Revistas Internacionais